ALMIRALL news, videos and press releases - Page 3
For more news please use our advanced search feature.
ALMIRALL - More news...
ALMIRALL - More news...
- Pablo Alvarez appointed to President and GM of Almirall US
- Almirall demonstrates resilient performance year to date despite COVID-19 impacts
- Almirall demonstrates resilient performance year to date despite COVID-19 impacts
- Almirall launches its second innovation initiative for dermatology-focused digital health start-ups
- Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines
- Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines
- HitGen and Almirall Announce Achievement of Milestone in Their Strategic Collaboration
- Almirall calls for collaborative innovation to advance new treatments for skin diseases
- Almirall Announces FDA Approval Of Updated Label For Seysara® (Sarecycline) Tablets
- Almirall Enters the IBEX 35
- Almirall Enters the IBEX 35
- Almirall signs a strategic agreement with 23andMe to license rights of a bispecific monoclonal antibody that blocks all three isoforms of IL-36 cytokine
- Almirall and WuXi Biologics Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
- Almirall enters into an option agreement to acquire Bioniz Therapeutics and to establish a broad research agreement to further expand its innovative pipeline in medical dermatology
- Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases
- WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
- WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
- Almirall LLC Announces The Publication Of Long-Term Safety Data For The Use Of Seysara® (Sarecycline) Tablets In Patients 9 Years Of Age And Older
- Aczone® (dapsone) Gel, 7.5% Now Approved for the Topical Treatment of Acne Vulgaris in Patients 9 Years of Age and Older
- Almirall Issues Call For Grant Submissions For Development of New Immunodermatology Therapies
- Almirall Partners With AARS To Raise Awareness About The Burden Of Disease And Importance Of Education For Dermatology Professionals For National Acne Awareness Month
- Almirall Recognized As Distinguished Corporate Leader By American Skin Association - Unveiled Patient-Driven Purpose
- Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
- Almirall enters into a definitive agreement to divest ThermiGen, its medical device aesthetics business
- Almirall Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
- Novel Oral Antibiotic Treatment Seysara™ (sarecycline) Now Available
- Almirall LLC Launches New Name at Fall Clinical Dermatology Congress
-
Almirall
-
Almirall
- Sun Pharma to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab, Achieves Primary End Point in Both Phase-3 Studies in Patients with Moderate-to-Severe Plaque Psoriasis
